CNS Specific Antisense Oligonucleotide Market, By Drug (Approved and Pipeline), By Indication (Hered

Published Date: | Report Code : HC2068079


CNS Specific Antisense Oligonucleotide Market, By Drug (Approved and Pipeline), By Indication (Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy, Spinal Muscular Atrophy, and  Huntington’s Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region (North America, Europe, Asia Pacific, Middle East & Africa, and South America) – Market Size & Forecasting To 2028

COVID-19 Impact : Our team has been closely monitoring the current developments to identify the potential impact of COVID-19 on stakeholders and business processes across the value chain of industries. A special section about COVID-19 will be covered with the report to help companies in defining sustainable strategies.

Domain : Healthcare

Report Code : HC2068079

Status : Upcoming

The Global CNS Specific Antisense Oligonucleotide Market was valued at USD xx Billion in 2019 and is anticipated to grow at a CAGR of xx% during the forecast period. CNS-specific antisense oligonucleotide plays a crucial role in modern healthcare, as it functionsat the messenger RNA level before the protein is formed. This helpsinhibit the expression of certain disease-causing genes. It is used for the treatment of neurodegenerative disorders and relatedrare diseases.

It has the potential of being used as a therapeutic agent, asit blocks the disease processes by altering the metabolic pathway of a particular protein. It is done by the binding the Antisense Oligonucleotide to mRNA,from which that protein is normally synthesized. Binding of Antisense oligonucleotide blocks the ability of ribosomes to move along the messenger RNA, preventing the synthesis of protein.

Antisense oligonucleotide for CNS has been successfully developed to treat spinal muscular atrophy. It is a promising drug for the treatment of CNS disorders due to its specific molecular targeting and extended pharmacologicalproperties. It can elicit their pharmacological effect by several means, including RNase mediate RNA degradation or targeted modification of RNA splicing. Currently, for the treatment of neurological disease, the delivery ofantisense oligonucleotide to their site of action in the CNS requires direct delivery to the central compartment, as these molecules do not readily cross the blood brain barrier.

Increasing prevalence of neurodegenerative disease is a major factor in driving the CNS specific antisense oligonucleotide market growth.Key trends in the market are rich product pipeline and the launch of new products for rare diseases associated with CNS disorder. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth.

Market players are increasingly investing in research in order to develop CNS specific antisense oligonucleotide for treating various rare diseases. Also, market players are committed to offer new and improved products in order to meet the critical needs of patients. Key players operating in the market are also focused on adopting acquisition strategies or collaboration in order to gain access to innovative products and expand their product offerings in targeted markets.

Government support for antisense oligonucleotide has been providing many opportunities to its market to grow across the globe. Changing regulations and pharmaceutical companies’ increasing focus on developing antisense oligonucleotidefor various neurological disorders have increased market demand.

However, toxic effects and high cost of treatment and developments are expected to hinder the market growth. Despite several advancements at clinical levels, the delivering of active oligonucleotide to the actual site within the target cells remains one of the major challenges that is hindering the growth of the global antisense oligonucleotide sector.

End-User Outlook:

Based on end-user, the CNS specific antisense oligonucleotides market has been segmented into pharmaceutical, hospital pharmacy, retail pharmacy, and online pharmacy.

Regional Outlook:

Based on the region, the global CNS specific antisense oligonucleotides market segmentation includes North America, Western Europe, Eastern Europe, Asia Pacific, the Middle East, and the Rest of the World.

North America is predicted to dominate the global market for CNS specific antisense oligonucleotides. The market in North America is expected to be driven by an exponential rise in the number of pharmaceutical companies performing clinical trials for the production of promising medicines, recent FDA approvals and product launches, and an increase in the understanding of the treatment of neurological disorders. For example, aGeneTx Biotherapeutics LLC has obtained the orphan drug designation for GTX-101 and is suggested for the treatment of GTX-101 and Angelman syndrome.

The report analyses factors affecting theCNS Specific Antisense Oligonucleotide Market for both demand and supply.It further analyses the market dynamics such as drivers, restraints, opportunities, and future trendsduring the forecast years. The report also provides a comprehensive Porter’s model analysis on theCNS Specific Antisense Oligonucleotide Market for all six regions, viz, North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and the Rest of the world.

Competitive Landscape

The key market players are adopting inorganic development strategies like the acquisition of local brands. Similarly, other business models such as joint ventures and collaborations are helping prominent vendors to strengthen their presence in the CNS Specific Antisense Oligonucleotide Market and expand their product portfolio. The key leading players in the global CNS Specific Antisense Oligonucleotide Market include the Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., and Q-STATE BIOSCIENCES, INC.,among others.

This report also includes the profiles of key CNS Specific Antisense Oligonucleotide Market companies, along with their SWOT analysis and market strategies. In addition, these competitive landscapes provide a detailed description of each company including future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launch, new product developments, and other latest industrial developments.

Key Developments in CNS Specific Antisense Oligonucleotide Market:

  • In November 2018, Q-State Biosciences, Inc. joined with Pairnomix, LLC to create the innovative and breakthrough medicine for the treatment of rare and devastating central nervous system diseases.
  • In October 2018,Alnylam Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults

What Does This Report Provide?

This report provides a detailed understanding of the global CNS Specific Antisense Oligonucleotide Market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

CNS Specific Antisense Oligonucleotide Market Segmentation:

By Drug:

  • Approved 
  • Pipeline

By Indication:

  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington’s Disease

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

North America CNS Specific Antisense Oligonucleotide Market

  • North America, by Country
    • US
    • Canada
    • Mexico
  • North America, by Drug
  • North America, by Indication 
  • North America, by Distribution Channel

Europe CNS Specific Antisense Oligonucleotide Market

  • Europe, by Country
    • Germany
    • Russia
    • UK
    • France
    • Italy
    • Spain
    • The Netherlands
    • Rest of Europe 
  • Europe, by Drug
  • Europe, by Indication 
  • Europe, by Distribution Channel

Asia Pacific CNS Specific Antisense Oligonucleotide Market

  • Asia Pacific, by Country
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Indonesia
    • Rest of Asia Pacific 
  • Asia Pacific, by Drug
  • Asia Pacific, by Indication 
  • Asia Pacific, by Distribution Channel

Middle East & Africa CNS Specific Antisense Oligonucleotide Market

  • Middle East & Africa, by Country 
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East & Africa
  • Middle East & Africa, by Drug
  • Middle East & Africa, by Indication 
  • Middle East & Africa, by Distribution Channel

South America CNS Specific Antisense Oligonucleotide Market

  • South America, by Country 
    • Brazil
    • Argentina
    • Colombia
  • Rest of South America
  • South America, by Drug
  • South America, by Indication 
  • South America, by Distribution Channel

Reasons to Buy This Report:

  • Market size estimation of the CNS Specific Antisense Oligonucleotide Market on a regional and global basis
  • Unique research for market size estimation and forecasts
  • Profiling of major companies operating in the market with key developments
  • Broad scope to cover all the possible segments helping every stakeholder in the market


We provide customization of the study to meet specific requirements:

  • By Segment
  • By Sub-segment
  • By Region/Country

For more information, contact: [email protected]

License Offering

Single User (PDF)


Multi User (PDF)


Enterprise User (PDF)


Get Regional Report @ USD 2000 Only

Your personal details are secure. Privacy Policy

Buy Chapters of Sections

Avail customized purchase options to meet your exact research needs.

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities
Detailed Coverage

Detailed scope covering all the major segments in the market

Meticulous Data Validations

In line data validations to ensure data precision


Market recommendations supporting decision making processes

Analyst Support

Round the clock analyst support to resolve your queries

Free Customization

Up to 15% additional free customization to meet your specific requirements

15% Free Customization

Share your Requirements

Questions?  Speak to an Analyst

Your personal details are secure. Privacy Policy